Navigation Links
Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP

ts receiving PROMACTA and placebo respectively. Other AEs included nausea, nasopharyngitis, diarrhea and vomiting.

About PROMACTA

PROMACTA (eltrombopag olamine) is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets, and thus can be considered a platelet growth factor.(4) The safety profile will be further examined in ongoing clinical trials. PROMACTA was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. It is being developed by GlaxoSmithKline. PROMACTA is an investigational compound that has not received regulatory approval in any market for any indication at this time.

Ongoing Trials

Several PROMACTA trials investigating the short- and long-term treatment of chronic ITP are currently open and enrolling.(5) EXTEND (Eltrombopag eXTENded Dosing Study) is an open-label study for patients who had participated in previous PROMACTA trials and wished to take PROMACTA for the long-term treatment of their chronic ITP. RAISE (RAndomized placebo controlled ITP Study with Eltrombopag) is a global, randomized, double-blind, placebo-controlled Phase III trial currently assessing the safety, efficacy and tolerability of PROMACTA in a long-term treatment setting (up to six months) involving 189 patients across 135 centers in 26 countries. REPEAT (Repeat ExPosure to Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will involve 50 patients with chronic ITP and will assess the safety and efficacy of repeated administration of PROMACTA. For further information on the trials, visit http://www.itpstudy.com or http://www.clinicaltrials.gov.

About Idiopathic Thrombocytopenic Purpura'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
11. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:4/24/2014)... Nancy Chiaravalloti, PhD, of Kessler Foundation was named the ... City, New Jersey. Dr. Chiaravalloti spoke on April 24, ... topic of "Treating Cognitive Deficits Following Neurological Illness and ... a part of the long legacy of the Mendel ... "The field of rehabilitation research is a rewarding one. ...
(Date:4/24/2014)... Baker,s yeast is giving scientists a better understanding of ... and illness world-wide. , When two or more ... suppress or enhance the effectiveness of the other. ... These types of interactions are a major cause of ... limits on the practical scope of drug studies in ...
(Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
(Date:4/24/2014)... Fibroblasts, cells long thought to be boring and irrelevant, ... with heart disease. , Researcher Dr Milena Furtado, and ... at Monash University, found the heart cell fibroblast is ... for a healthy beating heart. , In research published ... found that cardiac fibroblasts are unique cells due to ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation scientist named 63rd Mendel Lecturer by St. Peter's University 2Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2
... the US consumer product safety commission. This number is far ... are mainly related to the children as they are the ... in an increase in the emergency room visit. ... the sidewalk, through crowded malls and playgrounds. , ...
... cause of concern as most of them are related to ... health problems due to which people abstained from work. ... and Development (CIPD) on about 30,000 workers revealed that mental ... to muscle related problems like bad back. ,The ...
... of Alzheimer's disease nationwide, both the New York State ... a resolution aimed at raising awareness of the importance ... brain disorder. ,The resolution declared November 2007 ... as Memory Screening Day in New York State. ...
... Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and ... been completed in the United States using the OrthoGlide ... implant designed to relieve chronic, disabling pain, due to ... ,"There has been a significant increase in ...
... products and medicines has the potential to reach Rs.120 billion ... of exclusive export promotion zones (EPZ) across India, says ... accelerated with the setting up of EPZs in about 12 ... over 25 percent in countries like the US, Britain, Spain, ...
... also known as marijuana or ganja, can help in ... occur when body tissues are attacked by its own ... at the University of Bonn, used tetrahydrocannabinol (THC), the ... and found that it reduced skin allergies. ...
Cached Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Mental Illness Foremost Reason for Absenteeism 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 3Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: